Reliability of Reflotron in Testing of Total Cholesterol

Reliability of Reflotron in Testing of Total CholesterolReliability of Reflotron in Testing of total Cholesterol and Urea in Non- centralized medical SettingIntroductionPoint-of-care testing (PoCT) has been defined as those analytical patient-testing activities provided within the institution, however performed outside the physical facilities of the clinical laboratories (1). There has been a growing interest in point-of-care testing (PoCT) because of its advantages over standard laboratory procedures, it provides timely information to aesculapian teams, facilitating rational, time-critical decisions, and has been demonstrated to improve patient outcomes in critical care settings (2). At least a dozen portable cholesterin and urea testing performers excite been designed for use in alliance and office settings. These instruments have made mass coatings for these risk factors feasible and thus are now in far-flung use for this purpose (3).Dys lipoidemia including both hyper chol esterolemia and hypertriglyceridemia represent significant risk factors for the development of peripheral artery diseases and negative health outcomes (4, 5).High blood cholesterol increases the risk of heart disease, is a major modifiable risk factor, and contributes to the leading cause of death in the USA (6,7).Chronic kidney disease (CKD) is now recognise as a major world-wide health problem (8). A method for the estimation of the urea in blood coming from individual organs and for clinical purposes must be efficient when only small quantities of blood can be obtained (9).Aim of workIn Arar city many non- centralized Medical Setting used Reflotron for medical analysis and diagnosis disease. The purpose of this study was to assess the validity of Reflotron in the testing of total cholesterol and urea for screening and diagnosis in Arar city.MethodsCross sectional study held in Arar city in the period from 1 November 2013 to 10 November 2013, 30 blood sample was interpreted and m easured by Reflotron apparatus and the results was rechecked by Dimension RXI MAX apparatus to compare in the midst of the results between 2 methods.Approximately 20ml of blood was imperturbable from all(prenominal) participant, after fasting for 12h, using standardized venipuncture techniques in the antecubital vein in the bend of the elbow. In order to overcome technician error, both drops of blood (30l) were collected immediately from the previously drawn venous sample by drawing blood into the capillary electron tube from the opening in the top of the venous tube before centrifuging the venous sample, rather than sticking the finger.Statistical analysis was done by SPSS 20 and suitable statistical methods were used, pResultsTable (1) Comparison between Reading of Reflotron and Dimension RXI MAX testTable 1 shows that the correspond of urea was 65.2246.3 by Dimension RXI MAX apparatus while it was 63.7341.1 by Reflotron, as regards Total cholesterol mean by Dimension RXI MA X and Reflotron was 150.0438.9 and 167.740.3 respectively, the difference between the reading of the ii apparatuses was not statistically significant in both Urea and cholesterol.Table (2) Mean Percent of change between Reflotron and Dimension RXI MAX test in urea and cholesterolTable 2 shows that the mean percent of change between Reflotron and Dimension RXI MAX test in urea and cholesterol was -0.4% and 12.5% respectivelyDiscussionThe Reflotron has been marketed aggressively for use in community screening programs. The marketing has focused heavily on the instruments relatively low cost, ease of operation, and accuracy. This strategy has resulted in the widespread use of this instrument in blood cholesterol screenings. The Reflotron has been studied previously using various settings, sample sizes, and methodologies (10).This study compared the same blood sample using dry alchemy by the portable analyzer Reflotron plus and wet chemistry by Dimension RXI MAX apparatus.The MultiCar e systems are pocket-sized reflectance photometers, in which the intensity of the polish developed from a chromogen reaction being proportional to the concentration of the cholesterol or urea in the blood. The results of the MultiCare method compared with the reference method demonstrated bang-up agreement between the 2 methods, the difference between the reading of the two apparatuses was not statistically significant in both Urea and cholesterol with a mean difference of 12.5% and 0.4% for cholesterol and urea, respectively. The availability of POCT lipid monitors has increased in recent years, any POCT must be validated for bias and imprecision to discipline that appropriate medical decisions and population screenings are made (11-17). The National Cholesterol fostering Program (NCEP) in the United States recommended bias goals of 3% and 5% for cholesterol and triglycerides, respectively.Conclusion The portable analyzer Reflotron provided clinically relevant underestimations of total cholesterol values comparison with Dimension RXI MAX, whereas, urea values urea values satisfied. Consequently, lipid values obtained using the Reflotron may be utile for screening, but the Reflotron should not be used as a diagnostic tool. Urea values useful for screening and diagnosis kidney diseases.ReferencesU.S. Department of Health and Human Services, National institutes of Health. Point-of-Care Diagnostic Testing Fact Sheet. Jul 2007.Birkhahn RH, Haines E, Wen W, Reddy L, Briggs WM, Datillo PA (2011). Estimating the clinical impact of bringing a multimarker cardiac panel to the bedside in the ED. Am J Emerg Med, 29(3)304-8.Havas, Stephen Bishop, Robert et al Performance of the Reflotron in Massachusetts Model System for blood cholesterol screening program. American journal of public health Mar 199282,3, ProQuist central.Davis, C.L., Harmon, W.E., Himmelfarb, J., Hostetter, T., Powe, N., Smedberg, P., Szczech, L.A. and Aronson, P.S. 2008 World Kidney Day 2008 think g lobally, speak locally. Journal of the American Society of Nephrology 19, 41316.Sullivan DR. Screening for cardiovascular disease with cholesterol. Int J Clin Chem 20023154960.State-specific cholesterol screening trends-United States, 19911999. MMWR Morb Mortal Wkly Rep 2000284 p. 13745.Cheng AY, Leiter LA. (2006). Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel ternary guidelines. Curr Opin Cardiol 21(4)400404.Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001).Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 28524862497.Volles DF, McKenney JM, Miller WG, Ruffen D, Zhang D. Ana- lytic and clinical performance of two compact cholesterol-testing devices. Pharmacotherapy 19981818492.Havas S, Bishop R, Koumjian L, Reisma n J, Wozenski S.Performance of the Reflotron in Massachusetts model system for blood cholesterol measurement. Am J PublicHealth 19928245861.Shephard MD, Mazzachi BC, Shephard AK. Comparative perfor- mance of two point-of-care analysers for lipid testing. Clin Lab 2007535616.Stein JH, Carlsson CM, Papcke-Benson K, Einerson JA, McBride PE, Wiebe DA. Inaccuracy of lipid measurements with the portable Cholestech L.D.X analyzer in patients with hypercho- lesterolemia. Clin Chem 20024828490.du Plessis M, Ubbink JB, Vermaak WJ. Analytical quality of near- patient blood cholesterol and glucose determinations. Clin Chem 200046108590.Gottschling HD, Reuter W, Ronquist G, Steinmetz A, Hattemer A. Multicentre evaluation of a non-wipe system for the rapid determination of total cholesterol in capillary blood, Accutrend Cholesterol on Accutrend GC. Eur J Clin Chem Clin Biochem 19953337381.Laboratory calibration Panel of the National Cholesterol Education Program. Current status of blood choleste rol measurement in clinical laboratories in the United States a bailiwick from the Laboratory Standardization Panel of the National Cholesterol Education Program. Clin Chem 198834193201.Carey M, Markham C, Gaffney P, Boran C, Maher V. Validation of a point of care lipid analyser using a hospital based reference laboratory. Ir J Med Sci 2006175305.Luley C, Ronquist G, Reuter W, et al. Point-of-care testing of triglycerides evaluation of the Accutrend triglycerides system. Clin Chem 20004628791.